A nonsense variant in the CD36 gene (Y325*) accounts for 9% of dilated cardiomyopathy cases among individuals of African ancestry, outpacing even TTN truncating variants previously considered the leading genetic cause. Analysis of 82,623 African ancestry participants across four major biobanks revealed CD36 Y325* homozygotes face 4.8-fold increased DCM odds, while heterozygotes show 1.4-fold elevated risk. This finding fundamentally reframes our understanding of heart failure genetics across populations. While TTN variants were discovered primarily in European cohorts, this CD36 variant is ancestry-specific and explains disease burden that established genes could not account for. The discovery highlights critical gaps in genetic research diversity—most cardiovascular genetic studies have focused on European populations, potentially missing key disease drivers in other ancestries. For the millions of Americans of African descent at elevated heart failure risk, this variant represents a concrete target for genetic screening and potentially personalized prevention strategies. However, as this research awaits peer review, the clinical implications require validation before implementation. The work represents a paradigm shift toward more inclusive genetic medicine that could reduce longstanding health disparities in cardiovascular care.